Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Jul. 31, 2020
Acceleron Collaboration Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenues		$ 1.0
Deferred Revenue	$ 0.0	0.6
Reimbursement Payment Recieved	4.9
Acceleron Collaboration Agreement | Research Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Research Development And Sales Arrangement Amount Received Upon Achievement Of Milestone		2.0
MyoKardia Collaboration and License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non refundable upfront payment received	10.0
Revenues	2.8	5.3
Deferred Revenue		0.9	$ 3.2
Deferred revenue current and non-current		0.9
Reimbursement Payment Recieved	7.2		5.6
Unbilled Accounts Receivable Related To Reimbursable Research And Development Cost	0.5	0.2
Upfront payment					$ 10.0
Payment for prepaid research funding	2.5	$ 2.5			2.5
Prepaid research funding payment received				$ 2.5
MyoKardia Collaboration and License Agreement | Maximum
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment for certain identified targets					298.5
Milestone payment for certain other identified targets					$ 150.0
MyoKardia Collaboration and License Agreement | Clinical and Regulatory Milestones
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate amount receivable on achievement of milestone	2.5		2.5
Research Development And Sales Arrangement Aggregate Amount Receivable Upon Achievement Of Milestone	$ 2.5		$ 2.5